Phase 2 — Benign Prostatic Hyperplasia (BPH)

The purpose of the study is to assess the safety and effectiveness of Aptocine in patients with lower urinary tract symptoms [LUTS] due to benign prostatic hyperplasia.

For more information about this trial, please visit the trial registration page at ClinicalTrials.gov:

• Go to ClinicalTrials.gov, Trial ID # NCT00918034